Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight

The Prader-Willi syndrome market is expected to grow steadily, driven by increasing disease awareness, improved diagnosis, and the development of novel targeted therapies such as WAKIX (Harmony Biosciences), ARD-101 (Aardvark Therapeutics), PBF-999 (Palobiofarma), CSTI-500 (ConSynance Therapeutics), HBS-102 (Harmony Biosciences), Setmelanotide (Rhythm Pharmaceuticals), and others.

LAS VEGAS, Oct. 12, 2026 /PRNewswire/ -- Recently published Prader-Willi Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Prader-Willi syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Prader-Willi Syndrome Market Summary

• The market size of Prader-Willi syndrome in the 7MM was more than USD 700 million in 2025, which is further expected to increase by 2036.
• The United States accounted for the largest Prader-Willi syndrome treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2025, the 7MM had approximately 26,000 diagnosed prevalent cases of PWS. 
• Leading Prader-Willi syndrome companies, such as Harmony Biosciences, Aardvark Therapeutics, Palobiofarma, ConSynance Therapeutics, Rhythm Pharmaceuticals, Bright Minds Biosciences, Tonix Pharmaceuticals, epm Therapeutics, and others, are developing new Prader-Willi syndrome treatment drugs that can be available in the Prader-Willi syndrome market in the coming years. 
• The promising Prader-Willi syndrome therapies in clinical trials include WAKIX, ARD-101, PBF-999, CSTI-500, HBS-102, Setmelanotide, BMB-101, BMB-105, TNX-2900, EPM301, and others.

Discover the future of the Prader-Willi syndrome therapeutics market @ https://www.delveinsight.com/report-store/prader-willi-syndrome-market

Key Factors Driving the Growth of the Prader-Willi Syndrome Market 

• Rising Prader-Willi Syndrome Prevalence: As per DelveInsight's analysis, in 2025, the US accounted for approximately 12,200 diagnosed prevalent cases of PWS. These are expected to increase during the forecast period (2026−2036) owing to improved screening methods leading to earlier detection, changes in lifestyle and environmental factors, and advancements in medical technology allowing for better diagnosis and treatment.
• Growing Demand for Effective Treatments: PWS is associated with hyperphagia, obesity, growth abnormalities, and endocrine complications, creating a significant need for therapies that address multiple disease manifestations. The limited availability of disease-modifying treatment options is encouraging continued therapeutic development.
• Increasing Use of Growth Hormone Therapy: Growth hormone treatment plays an important role in managing growth failure and body-composition abnormalities associated with PWS. Continued clinical experience and wider recognition of its benefits are supporting demand for growth hormone-based management.
• Advances in Genetic and Molecular Diagnostics: Improvements in molecular and genetic testing are enabling more accurate confirmation of PWS and differentiation from other causes of developmental and metabolic abnormalities. Earlier diagnosis can facilitate timely multidisciplinary management and long-term monitoring.
• Launch of Emerging Prader-Willi Syndrome Medications: The dynamics of the Prader-Willi syndrome market are expected to change in the coming years due to the launch of emerging therapies such as WAKIX (Harmony Biosciences), ARD-101 (Aardvark Therapeutics), PBF-999 (Palobiofarma), CSTI-500 (ConSynance Therapeutics), HBS-102 (Harmony Biosciences), Setmelanotide (Rhythm Pharmaceuticals), BMB-101 and BMB-105 (Bright Minds Biosciences), TNX-2900 (Tonix Pharmaceuticals), EPM301 (epm Therapeutics), and others.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that the introduction of new therapies, particularly those with novel mechanisms of action or broader symptom coverage, may fragment prescriber preferences and intensify competition for patient share. This could pressure VYKAT XR's pricing flexibility, market uptake, or label expansion strategies, particularly if newer entrants demonstrate superior efficacy, safety, or convenience.

Prader-Willi Syndrome Market Analysis

• Treatment strategies for Prader-Willi syndrome are tailored to the specific symptoms experienced by each patient. 
• Growth hormone replacement therapy remains the only FDA-approved treatment for children with PWS; however, its indication is limited to addressing growth failure and does not target key manifestations such as hyperphagia or behavioral abnormalities.
• The FDA has approved three growth hormone products for use in PWS: GENOTROPIN, NORDITROPIN, and OMNITROPE. By comparison, the EMA and MHLW have approved only GENOTROPIN for PWS. OMNITROPE is also authorized as a biosimilar for PWS in Europe.
• In March 2025, the US Food and Drug Administration (FDA) approved VYKAT XR (diazoxide choline) extended-release tablets, formerly known as Diazoxide Choline Controlled Release (DCCR), for the treatment of hyperphagia in adults and children aged 4 years and older with PWS. Following regulatory approval, VYKAT XR was officially launched, with patient treatment initiated in April 2025.
• The development of therapies targeting PWS-associated hyperphagia has faced several challenges. Alize Pharma's AZP-531 demonstrated efficacy in a Phase II trial in 2016 but did not advance into later-stage development. In the same year, Zafgen's beloranib achieved positive results in a Phase III trial but was subsequently discontinued because of safety concerns.
• Several companies are currently developing potential therapies for PWS, including Harmony Biosciences, with WAKIX (pitolisant) and HBS-102; Aardvark Therapeutics, with ARD-101; Palobiofarma, with PBF-999; and ConSynance Therapeutics, with CSTI-500, among other industry participants.

Prader-Willi Syndrome Competitive Landscape

Some of the Prader-Willi syndrome medications under development include WAKIX (Harmony Biosciences), ARD-101 (Aardvark Therapeutics), PBF-999 (Palobiofarma), CSTI-500 (ConSynance Therapeutics), HBS-102 (Harmony Biosciences), Setmelanotide (Rhythm Pharmaceuticals), BMB-101 and BMB-105 (Bright Minds Biosciences), TNX-2900 (Tonix Pharmaceuticals), EPM301 (epm Therapeutics), and others. 

Harmony Biosciences' WAKIX (pitolisant) is a selective histamine H₃ receptor antagonist/inverse agonist. The FDA has approved WAKIX for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. Although pitolisant is not currently approved for patients with Prader-Willi syndrome (PWS), it is being investigated as a potential treatment for the condition. The U.S. FDA has granted pitolisant Orphan Drug designation for the treatment of PWS.

Aardvark Therapeutics' ARD-101 is an investigational, orally administered small-molecule therapy being developed to address hyperphagia-related behaviors in patients with PWS. Its proposed mechanism involves stimulating gut-localized secretion of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), which may help reduce hyperphagia-related behaviors. ARD-101 is currently undergoing Phase III development in the HERO trial.

Palobiofarma's PBF-999 is an investigational, innovative phosphodiesterase 10 (PDE10) inhibitor developed by Palobiofarma. Preclinical studies have demonstrated potent and selective inhibition of the PDE10 enzyme, which plays an important role in regulating cyclic nucleotide levels, key signaling molecules involved in brain function. A Phase II clinical trial is currently evaluating PBF-999 in patients with PWS. The compound has previously been assessed in three clinical studies, where an appetite-suppressing effect was observed. Based on these findings, Palobiofarma has initiated a new clinical study to evaluate the safety and efficacy of PBF-999 in reducing hyperphagia among adults with PWS.

ConSynance Therapeutics' CSTI-500 is an investigational triple monoamine reuptake inhibitor (TRI) that targets serotonin, dopamine, and norepinephrine by inhibiting their respective transporters—SERT, DAT, and NET. These neurotransmitters play important roles in regulating behavior, appetite, feeding, and mood. CSTI-500 is an orally administered New Chemical Entity (NCE) designed to potentially restore key neurotransmitter balance in patients with PWS.

The anticipated launch of these emerging therapies are poised to transform the Prader-Willi syndrome market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Prader-Willi syndrome market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the medication for Prader-Willi syndrome @ Prader-Willi Syndrome Medication

Recent Developments in the Prader-Willi Syndrome Market

• In June 2026, ConSynance Therapeutics announced that the first participant has been dosed in its Phase 2a clinical trial evaluating CSTI-500 for the treatment of Prader-Willi syndrome (PWS), representing a significant clinical milestone for the program.
• In June 2026, Soleno Therapeutics reported late-breaking data at ENDO 2026 demonstrating that restarting VYKAT® XR (diazoxide choline) extended-release tablets after a 16-week randomized withdrawal period sustained improvements in hyperphagia and behavioral symptoms associated with Prader-Willi syndrome (PWS) over two years.
• In May 2026, Aardvark Therapeutics said the FDA has imposed a full clinical hold on its drug candidate targeting extreme hunger in patients with Prader-Willi syndrome, bringing its late-stage trials to a halt.
• In April 2026, Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc. announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, valuing the transaction at approximately $2.9 billion in equity value.
• In April 2026, the Foundation for Prader-Willi Research (FPWR) announced a venture philanthropy investment in ConSynance Therapeutics to support the advancement of CSTI-500, ConSynance' s investigational therapy for the treatment of behavioral dysregulation and hyperphagia in PWS.
• In February 2026, Aardvark Therapeutics announced that Institutional Review Board (IRB) approval has been granted in the US for an amended protocol to its ongoing Phase III HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with PWS. The amended protocol, submitted to the US FDA, lowers the minimum age of eligibility for trial participation from 10 to 7 years old.

Prader-Willi Syndrome Epidemiology Segmentation

The Prader-Willi syndrome epidemiology section provides insights into the historical and current Prader-Willi syndrome patient pool and forecasted trends for the leading markets. In the US, roughly 70% of the PWS patients are children, whereas in Japan, the child population contributes to roughly 55% only.

The Prader-Willi syndrome treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of PWS
• Total Diagnosed Prevalent Cases of PWS
• Age-specific Cases of PWS
• PWS Case by Genetic Subtype

Scope of the Prader-Willi Syndrome Market Report

• Prader-Willi Syndrome Patient Population Forecast
• Prader-Willi Syndrome Therapeutics Market Size
• Prader-Willi Syndrome Pipeline Analysis
• Prader-Willi Syndrome Market Size and Trends
• Prader-Willi Syndrome Market Opportunity
• Prader-Willi Syndrome Market Unmet Needs
• KOL's Views on Prader-Willi Syndrome
• Prader-Willi Syndrome Market Access and Reimbursement

Download the report to understand the recent developments in the Prader-Willi Syndrome treatment market @ Prader-Willi Syndrome Clinical Trials

Table of Contents

Related Reports

Prader-Willi Syndrome Clinical Trial Analysis

Prader-Willi Syndrome Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Prader-Willi syndrome companies, including Harmony Biosciences, ACADIA Pharmaceuticals, Jazz Pharmaceuticals, Aardvark Therapeutics, ConSynance Therapeutics, and others.

Obesity Market

Obesity Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obesity companies, including Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.

Angelman Syndrome Market

Angelman Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Angelman syndrome companies, including GeneTx Biotherapeutics, GEXVal, Ionis Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, PTC Therapeutics, Roche, Sarepta Therapeutics, StrideBio, Taysha Gene Therapies, Ultragenyx Pharmaceutical, and others.

Fragile X Syndrome Market

Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Fragile X syndrome companies, including Confluence Pharmaceuticals, Ovid Therapeutics, Neuren Pharmaceuticals, Zynerba Pharmaceuticals, Tetra Therapeutics, Autifony Therapeutics, Prilenia Therapeutics, Alcobra Ltd., Seaside Therapeutics, Inc., Marinus Pharmaceuticals, Novartis Pharmaceuticals, Neuren Pharmaceuticals, Hoffmann-La Roche, Healx, Nova Mentis, Lysogene, Actinogen, Prilenia Therapeutics, Confluence Pharmaceuticals, Sentinel Oncology, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur

info@delveinsight.com 

+14699457679

www.delveinsight.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/prader-willi-syndrome-market-to-expand-by-2036-as-new-therapeutic-opportunities-address-unmet-clinical-needs--delveinsight-302905333.html

SOURCE DelveInsight Business Research, LLP